Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values

Prostate

Volumn 29, Issue SUPPL. 7, 1996, Pages 3-16

  Semjonow, Axel ^a,b   Brandt, Burkhard ^b   Oberpenning, Frank ^a   Roth, Stephan ^a   Hertle, Lothar ^a  

^a Institute of Clinical Chemistry   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

assay standardization; free PSA; interassay variability; PSA complexes; reference range; total PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FOLLOW UP; HUMAN; IMMUNOASSAY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; OSMOLARITY; PACKAGING; PROSTATE TUMOR; REFERENCE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY; TECHNIQUE;

HUMANS; IMMUNOASSAY; MALE; METHODS; OSMOLAR CONCENTRATION; PRODUCT LABELING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 0030339750     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0045(1996)7+<3::aid-pros1>3.0.co;2-t     Document Type: Conference Paper

References (112)

1. Littrup PJ, Goodman AC, Mettlin CJ, Murphy GP, Investigators of the American Cancer Society-National Prostate Cancer Detection Project: Cost analyses of prostate cancer screening: Frameworks for discussion. J Urol 152:1873-1877, 1994.
2. Allhoff E, de Riese W, Eifinger M, Pethke J, Jonas U: Prostate-specific antigen - comparative clinical appreciation of a serodiagnostic measure after 8 years of experience. World J Urol 7:12-16, 1989.
3. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, Igel TC, Kidd DD: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143:1146-1154, 1990.
4. Hammerer P, Loy V, Dieringer J, Huland H: Prostate cancer in nonurological patients with normal prostates on digital rectal examination. J Urol 147:833-836, 1992.
5. Wirth MP, Frohmüller HGW: Prostate specific antigen and prostate acid phosphatase in the detection of early prostate cancer and the prediction of regional lymph node metastases. Eur Urol 22:27-32, 1992.
6. Myrtle JF, Klimley PG, Ivor IP, Bruni JF: Clinical utility of prostate specific antigen (PSA) in the management of prostate cancer. Adv Cancer Diagnostics, Hybritech, Inc., San Diego, 1986.
7. Chan DW, Bruzek DJ, Oesterling JE, Rock RC, Walsh PC: Prostate specific antigen as a marker for prostatic cancer: A monoconal and a polyclonal immunoassay compared. Clin Chem 33:1916-1920, 1987.
8. Rock RC, Chan DW, Bruzek D, Waldron C, Oesterling J, Walsh P: Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen. Clin Chem 33:2257-2261, 1987.
9. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909-916, 1987.
10. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJJ, Petros JA, Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156-1161, 1991.
11. Babaian RJ, Miyashita H, Evans RB, Ramirez EI: The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: Relationship to gland volume and age. J Urol 147:837-840, 1992.
12. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH: Screening for prostatic carcinoma with prostate specific antigen. J Urol 147:841-845, 1992.
13. Glenski WJ, Klee GG, Bergstralh EJ, Oesterling JE: Prostate-specific antigen: Establishment of the reference range for the clinically normal prostate gland and the effect of digital rectal examination, ejaculation, and time on serum concentrations. Prostate 21:99-110, 1992.
14. Dalkin BL, Ahmann FR, Kopp JB: Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol 150:1837-1839, 1993.
15. Schambeck C, Stieber P, Schmeller N, Pahl H, Reiter W, Fateh-Moghadam A: Wertigkeit von fünf PSA-Assays aus methodischer und klinischer Sicht. Lab Med 18:418, 1994.
16. Stone NN, DeAntoni EP, Crawford ED, Prostate Cancer Education Council: Screening for prostate cancer by digital rectal examination and prostate-specific antigen. Results of Prostate Cancer Awareness Week, 1989-1992. Urology 44:18-25, 1994.
17. Dalkin BL, Ahmann FR, Kopp JB, Catalona WJ, Ratliff TL, Hudson MA, Richie JP, Scardino PT, Flanigan RC, Dekernion JB, Waters WB, Kavoussi LR, MacFarlane MT: Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma. Br J Urol 76:346-350, 1995.
18. Reissigl A, Pointner J, Horninger W, Ennemoser O, Strasser H, Klocker H, Bartsch G: Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: Results of a large screening study. Urology 46:662-665, 1995.
19. Speights VO Jr, Brawn PN, Foster DM, Spiekerman AM, Kuhl D, Riggs MW: Evaluation of age-specific normal ranges for prostate-specific antigen. Urology 45:454-457, 1995.
20. Gustafsson O, Norming U, Almgard LE, Fredriksson A, Gustavsson G, Harvig B, Nyman CR: Diagnostic methods in the detection of prostate cancer: A study of a randomly selected population of 2,400 men. J Urol 148:1827-1831, 1992.
21. Brawer MK, Beatie J, Wener MH, Vessella RL, Preston SD, Lange PH: Screening for prostatic carcinoma with prostate specific antigen: Results of the second year. J Urol 150:106-109, 1993.
22. Catalona WJ, Smith DS, Ratliff TL, Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270:948-954, 1993.
23. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 151:1283-1290, 1994.
24. Bangma CH, Kranse R, Blijenberg BG, Schröder FH: The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men. Urology 46:773-778, 1995.
25. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC: Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143:747-752, 1990.
26. Winter HI, Bretton PR, Herr HW: Preoperative prostate-specific antigen in predicting pathologic stage and grade after radical prostatectomy. Urology 38:202-205, 1991.
27. Waehre H, Wanderaas EH, Paus E, Fossa SD: Prediction of pelvic lymph node metastases by a prostate-specific antigen and prostatic acid phosphatase in clinical T3/T4 MO prostatic cancer. Eur Urol 22:33-38, 1992.
28. Corn BW, Hanks GE, Lee WR, Schultheiss T: Do the current subclassifications of stage T3 adenocarcinoma of the prostate have clinical relevance? Urology 45: 484-489, 1995.
29. Hammerer P, Huland H, Sparenberg A: Digital rectal examination, imaging, and systematic-sextant biopsy in identifying operable lymph node-negative prostatic carcinoma. Eur Urol 22:281-287, 1992.
30. Waldner M, Semjonow A, Rathert P, Hertle L: Prostataspezifisches Antigen vor radikaler Prostatektomie - Eine Hilfe zur Indikationsstellung? Urologe [B] 34:170-173, 1994.
31. Catalona WJ: Screening for prostatic cancer: Enthusiasm. Urology 42:113-115, 1993.
32. Chodak GW: Questioning the value of screening for prostate cancer in asymptomatic men. Urology 42: 116-118, 1993.
33. Goldschmidt AJW, Tunn UW, Altwein JE: Ökonomische und biometrische Aspekte zum Screening des Prostatakarzinoms. Aktuelle Urologie 24:342-350, 1993.
34. Handley MR, Stuart ME: The use of prostate specific antigen for prostate cancer screening: A managed care perspective. J Urol 152:1689-1692, 1994.
35. Semjonow A, Hamm M, Rathert P: Half-life of prostate-specific antigen after radical prostatectomy: The decisive predictor of curative treatment? Eur Urol 21: 200-205, 1992.
36. Semjonow A, Hamm M, Rathert P: Prediction of tumor recurrence after radical prostatectomy using elimination kinetics of prostate-specific antigen. World J Urol 11:218-220, 1993.
37. Goldrath DE, Messing EM: Prostate specific antigen: Not detectable despite tumor progression after radical prostatectomy. J Urol 142:1082-1084, 1989.
38. Takayama TK, Krieger JN, True LD, Lange PH: Recurrent prostate cancer despite undetectable prostate specific antigen. J Urol 148:1541-1542, 1992.
39. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 141:873-879, 1989.
40. Lightner DJ, Lange PH, Reddy PK, Moore L: Prostate specific antigen and local recurrence after radical prostatectomy. J Urol 144:921-926, 1990.
41. Abi-Aad AS, MacFarlane MT, Stein A, de Kernion JB: Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound. J Urol 147:952-955, 1992.
42. Newling DWW: Management of relapsed prostatic carcinoma following primary treatment. Eur Urol [Suppl] 24:87-93, 1993.
43. Smith RF, Smith SM, Austenfeld MS, Noble MJ, Reddy E, Smalley SA: Outcomes of patients with biochemical (PSA) failure following prostatectomy. J Urol [Suppl] 151:257, 1994.
44. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152:1850-1857, 1994.
45. Agha AH, Schechter E, Roy JB, Culkin DJ: Prostate specific antigen is metabolized in the liver. J Urol 155: 1332-1335, 1996.
46. Filella X, Cases A, Molina R, Jo J, Bedini JL, Revert L, Ballesta AM: Tumor markers in patients with chronic renal failure. Int J Biol Markers 5:85-88, 1990.
47. Semjonow A, Hamm M, Rathert P: Elimination kinetics of prostate-specific antigen: Serum and urine. Int J Biol Markers 9:15-20, 1994.
48. Veneziano S, Pavlica P, Querzé R, Nanni G, Lalanne MG, Vecchi F: Correlation between prostate-specific antigen and prostate volume evaluated by transrectal ultrasonography: Usefulness in diagnosis of prostate cancer. Eur Urol 18:112-116, 1990.
49. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147: 817-821, 1992.
50. Mettlin C, Littrup PJ, Kane RA, Murphy GP, Lee F, Chesley A, Badalament R, Mostofi FK: Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Cancer 74:1615-1620, 1994.
51. Semjonow A, Hamm M, Rathert P, Hertle L: Prostate-specific antigen corrected for prostate volume improves differentiation of BPH and organ-confined prostatic cancer. Br J Urol 73:538-543, 1994.
52. Wolff JM, Scholz A, Boeckmann W, Jakse G: Differentiation of BPH and prostate cancer employing prostatic-specific antigen density. Eur Urol 25:295-298, 1994.
53. Bangma CH, Kranse R, Blijenberg BG, Schröder FH: The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology 46:779-784, 1995.
54. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM: Serum prostate-specific antigen in a community-based population of healthy men - Establishment of age-specific reference ranges. JAMA 270:860-864, 1993.
55. Oesterling JE, Cooner WH, Jacobsen SJ, Guess HA, Lieber MM: Influence of patient age on the serum PSA concentration. Urol Clin North Am 20:671-680, 1993.
56. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O: A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 51:222-226, 1991.
57. Christensson A, Björk T, Nilsson O, Dahlen U, Matikainen M, Cockett ATK, Abrahamsson PA, Lilja H: Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 150:100-105, 1993.
58. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274:1214-1220, 1995.
59. Huber PR, Schmid HP, Mattarelli G, Strittmatter B, van Steenbrugge GJ, Maurer A: Serum free prostate-specific antigen: Isoenzymes in benign hyperplasia and cancer of the prostate. Prostate 27:212-219, 1995.
60. Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, Thiel R: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46:187-194, 1995.
61. Mitrunen K, Pettersson K, Piironen T, Björk T, Lilja H, Lövgren T: Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 41:1115-1120, 1995.
62. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, Stenman UH, Dowell B, Lovgren T, Lilja H: Free, complexed and total serum prostate specific antigen: The establishment of appropriate reference ranges for their concentrations and ratios. J Urol 154:1090-1095, 1995.
63. Chen YT, Luderer AA, Thiel RP, Carlson G, Cuny CL, Soriano TF: Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 47:518-524, 1996.
64. Carter BC, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215-2220, 1992.
65. Schmid HP, McNeal JE, Stamey TA: Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71:2031-2040, 1993.
66. Catalona WJ, Smith DS: Comparison of different serum prostate specific antigen measures for early prostate cancer detection. Cancer 74:1516-1518, 1994.
67. Riehmann M, Rhodes PR, Cook TD, Grose GS, Bruskewitz RC: Analysis of variation in prostate-specific antigen values. Urology 42:390-397, 1993.
68. Schambeck CM, Schmeller N, Stieber P, Jansen HM, Pahl H, Schneider W, Fateh-Moghadam A: Methodological and clinical comparison of the ACS prostate-specific antigen assay and the Tandem-E prostate-specific antigen assay in prostate cancer. Urology 46: 195-199, 1995.
69. Graves HCB: Standardization of immunoassays for prostate-specific antigen. A problem of prostate-specific antigen complexation or a problem of assay design? Cancer 72:3141-3144, 1993.
70. Plawker MW, Fleisher JM, Nitti VW, Macchia RJ: Primary care practitioners: An analysis of their perception of voiding dysfunction and prostate cancer. J Urol 155:601-604, 1996.
71. Vesella RL, Lange PH: Issues in the assessment of PSA immunoassays. Urol Clin North Am 20:607-619, 1993.
72. Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, Larsen FL: Multiple forms of prostate-specific antigen in serum: Differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 39:2483-2491, 1993.
73. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J: Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer. Lancet 344: 1594-1598, 1994.
74. Lilja H: Significance of different molecular forms of serum PSA. Urol Clin North Am 20:681-686, 1993.
75. Partin AW, Kelly CA, Subong ENP, Walsh PC, Chan DW, Wang TJ, Rittenhouse HG, Wolfert RL, Norton KC, McCormack R: Measurement of the ratio of free PSA to total PSA improves prostate cancer detection for men with total PSA levels between 4.0 and 10.0 ng/ml. J Urol [Suppl] 153:295, 1995.
76. Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a prostate specific antigen. Invest Urol 17:159-163, 1979.
77. Christensson A, Laurell CB, Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194:755-763, 1990.
78. Graves HCB, Wehner N, Stamey TA: Comparison of a polyclonal and monoclonal immunoassay for PSA: Need for an international antigen standard. J Urol 144: 1516-1522, 1990.
79. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lövgren T: Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem 37:1618-1625, 1991.
80. Graves HCB: Issues on standardization of immunoassays for prostate-specific antigen: A review. Clin Invest Med 16:415-424, 1993.
81. Graves HCB, Barren R: Progress towards PSA assay standards. In Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, Murphy G (eds): "Proceedings of the 3rd International Consultation on BPH." Scientific Communication International, Paris, 1996, pp 404-419.
82. Sokoloff RL, Esgate JA, Wang TJ, Strobel SA, Rittenhouse HG: Effect of prostate-specific antigen forms on PSA quantitation. J Urol [Suppl] 151:450, 1994.
83. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H, Oesterling JE: Molecular forms of prostate-specific antigen (PSA) and the human kallikrein gene family: Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era. Urology 45:729-744, 1995.
84. Roloff J, Büscher C, Walz PH: Bestimmung des Prostataspezifischen Antigens mit verschiedenen Testsätzen. Z Urol Poster 1:34-35, 1993.
85. Wener MH, Daun PR, Close B, Brawer MK: Method-to-method and lot-to-lot variation in assays for prostate-specific antigen. Am J Clin Pathol 101:387-388, 1994.
86. Brawer MK, Daum P, Petteway JC, Wener MH: Assay variability in serum prostate-specific antigen determination. Prostate 27:1-6, 1995.
87. Rippey JH, Wener MH, Horoszewicz J, Stenman UH, Klee GG, Belanger A, Maxim PE, Graves H, Howanitz J, Nakamura RM: American Cancer Society and College of American Pathologists workshop on PSA: Benefits and limitations - Workgroup #1: Standardization of PSA. Cancer 71:2678, 1993.
88. Jacobsen SJ, Lilja H, Klee GG, Wright GL, Petterson K, Oesterling JE: Comparability of the Tandem-R and IMx assays for the measurement of serum prostate-specific antigen. Urology 44:512-518, 1994.
89. Stamey TA: Second Stanford conference on international standardization of prostate-specific antigen immunoassays: September 1 and 2, 1994. Urology 45: 173-184, 1995.
90. Hortin GL, Bahnson RR, Daft M, Chan KM, Catalona WJ, Ladenson JH: Differences in values obtained with 2 assays of prostate specific antigen. J Urol 139:762-765, 1988.
91. Turkes A, Nott JP, Griffiths K: Prostate-specific antigen: Problems in analysis. Eur J Cancer 27:65 1991.
92. Cattini R, Robinson D, Gill O, Jolley N, Bacare Hamilton T: Measurement of prostate-specific antigen in serum using four different Immunoassays. Eur J Clin Chem Clin Biochem 32:181-185, 1994.
93. Römer M, Haeckel R, Capelli M, Rocipon J: The analytical performance of the Ciba Corning ACS:180 automated immunoassay system. Eur J Clin Chem Clin Biochem 32:395-407, 1994.
94. Yang N: Diagnostic and prognostic application of prostate-specific tissue markers: Prostate antigen (PA) and prostatic acid phosphatase (PAP). Clin Chem 30: 1057, 1984.
95. Myrtle JF, Shackelford W, Bartholomew RM, Wampler J: Prostate-specific antigen: Quantitation in serum by immunoradiometric assay. Clin Chem 29:1216, 1983.
96. Armbruster DA: Prostate-specific antigen: Biochemistry, analytical methods, and clinical application. Clin Chem 39:181-195, 1993.
97. Oesterling JE: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923, 1991.
98. Food and Drug Administration: Prostate specific antigen test approved. FDA Med Bull 25:4, 1995.
99. Burlington DB: FDA advises labs regarding off-label use of PSA assays. Clin Lab News 21:5, 1995.
100. Semjonow A, Oberpenning F, Brandt B, Junker R, Zechel C, Hertle L: The impact of free prostate-specific antigen (PSA) on the measurement of assays for total PSA. Urology, in press, 1996.
101. Pummer K, Wirnsberger G, Pürstner P, Stettner H, Wandschneider G: False positive prostate specific antigen values in the sera of women with renal cell carcinoma. J Urol 148:21-23, 1992.
102. Yang N: Endogenous antibody to prostate-specific antigen in women. Clin Chem 34:647-648, 1988.
103. Myrtle JF, Ivor LP: Measurement of prostate-specific antigen (PSA) in serum by a two-site immunometric method (Hybritech Tandem-R/Tandem-E PSA). In Catalona WJ, Coffey DS, Karr JP (eds): "Clinical Aspects of Prostate Cancer: Assessment of New Diagnostic and Management Procedures." New York: Elsevier Publishing Corp., 1989, pp 161-171.
104. Stray JE, Arfman EW, Vessella RL: The prostate specific protein-94 (PSP-94) crossreacts with anti-PSA monoclonal antibodies: Implications for PSA immunoassay standardization. J Urol 151:365, 1994.
105. Bankson DD, Lyon ME, Costales LV, Haver VM: The response of assays for total prostate specific antigen to changing proportions of "free" and α-antichymotrypsin bound PSA. Clin Chem 40:1009, 1994.
106. Semjonow A, Zechel C, Brandt B, Flammang F, Pepping B, Hertle L: Teststreifenuntersuchung: Prostataspezifisches Antigen (PSA). Urologe [A] [Suppl] 34:91, 1995.
107. Spitz J, Benz P, Köllermann M: Combined estimation of free and complexed PSA, first clinical results. In Klapdor R (ed): "Current Tumor Diagnosis." Munich: Zuckschwerdt Verlag, 1994, pp 305-308.
108. Sokoloff RL, Armour KW, Wolfert RL, Wang TJ, Howe TR: Immunoassay analytical recovery of prostate-specific antigen purified from seminal fluid. Clin Chem 40:1029, 1994.
109. Thorne T, Duncan M: Evaluation of Ciba Corning ACS 180: Prostate specific antigen assay. Clin Chem 40:1008, 1994.
110. Gibbons AB, Jonza JJ, Hart T, Hohnadel DC, D'Souza JP, Mayer TK: Three-way comparison of prostatic specific antigen (PSA) using Hybritech Photon ERA-QA, Abbott IMx, and Ciba-Corning ACS-180. Clin Chem 40:1012-1013, 1994.
111. Dnistrian AM, Schwartz MK, Smith CA, Nisselbaum JS, Fair WR: Abbott IMx evaluated for assay of prostate-specific antigen in serum. Clin Chem 38:2140-2142, 1992.
112. Jolley NL, Bacarese-Hamilton T: SR1 assays of alpha-fetoprotein, carcinoembryonic antigen, and prostate-specific antigen compared with corresponding established commercial assays. Clin Chem 40:895-899, 1994.